Content about GlaxoSmithKline

July 28, 2011
GSK expects to divest noncore OTC brands by late 2011, company says

GlaxoSmithKline expects to close the deal on the divestiture of several over-the-counter brands that were identified in April, the company stated Tuesday as part of its second-quarter earnings results.

July 25, 2011
Watson seeks to market generic Jalyn

Watson Pharmaceuticals is hoping to be the first to market a generic version of a GlaxoSmithKline drug for men with an enlarged prostate, Watson said.

July 25, 2011
Wellness drives sales in digestives, probiotics

Sales in the digestives aisle going forward look positive, especially as an aging population begins paying closer attention to healthy diets, including the right amount of dietary fiber to keep things “regular” and supplementation with probiotics for overall digestive health. 


July 22, 2011
Perrigo to market store-brand smoking-cessation gum

Perrigo on Thursday announced that it has received approval from the Food and Drug Administration to market a cinnamon-flavored, over-the-counter coated nicotine polacrilex gum USP in 2-mg and 4-mg strengths.

July 15, 2011
FDA approves Dr. Reddy’s generic anticoagulant drug

The Food and Drug Administration has approved a generic anticoagulant drug made by Dr. Reddy’s Labs and Alchemia.

July 11, 2011
Amneal launches three generic liquid drugs

Generic drug maker Amneal has launched three new liquid drugs, the company said Monday.

July 11, 2011
FDA approves combo vaccine for elderly patients

The Food and Drug Administration has approved a vaccine for preventing tetanus, diphtheria and whooping cough in elderly patients.

July 11, 2011
Stiefel introduces Revaleskin-branded anti-aging treatment

Stiefel, a GlaxoSmithKline company, has expanded its Revaleskin family of products with its new Revaleskin Illuminesse Brightening Complex.

June 21, 2011
Watson seeks to commercialize generic Avodart

Watson subsidiary Watson Labs is seeking approval for a drug designed to treat symptomatic benign prostatic hyperplasia in men with an enlarged prostate.

June 20, 2011
Three’s not a crowd: Top antacids hold their own


Good things come in three — like the three antacids that for the 52 weeks ended April 17 collectively generated more than $118 million in sales on top of the sales base they had established in the year-ago period.


June 14, 2011
Report: GSK brands on sales block peak interest

GlaxoSmithKline has garnered strong interest in its portfolio of legacy brands that were placed on the sales block earlier this year, according to a Reuters report published Tuesday. And that interest is likely to pick up in the coming months, GSK CEO Andrew Witty told reporters during a meeting of pharmaceutical industry executives.

June 13, 2011
GSK, Valeant receive FDA approval for Potiga

The Food and Drug Administration has approved a new drug for epilepsy made by GlaxoSmithKline and Valeant Pharmaceuticals International, the drug makers said Monday.

June 10, 2011
H1N1 flu variant may be resistant to certain treatments

A new strain of swine flu has emerged that appears somewhat resistant to flu drugs, according to published reports.

May 23, 2011
Pump up the iron


It’s not often a niche brand manufacturer attempts to resuscitate what has been for years a commoditized category. But that’s exactly what Meda Consumer Healthcare will be attempting to do with iron — establish a good/better/best proposition to a supplemented category best defined as mediocre.

May 19, 2011
Avandia to be available only by mail order in November, FDA asserts

A controversial GlaxoSmithKline drug for treating Type 2 diabetes no longer will be available through retail pharmacies as of Nov. 18, the Food and Drug Administration announced Wednesday.

May 11, 2011
Perrigo to settle litigation related to generic Cutivate

Drug maker Perrigo has reached a licensing agreement with Nycomed US that will allow it to launch a generic treatment for dermatitis in 2012, the company said.

April 27, 2011
OTC Perspectives to honor top marketers

OTC Perspectives magazine on Tuesday named its third annual list of "Top OTC/HBA Marketers of the Year."

April 26, 2011
Lamictal XR receives FDA approval as monotherapy

The Food and Drug Administration has approved a new indication for an epilepsy drug made by GlaxoSmithKline, the drug maker said Monday.

April 21, 2011
GSK applauds agreement to support global preparedness against pandemic influenza

Companies that make vaccines, drugs and diagnostic tests for influenza will become key stakeholders in the World Health Organization’s Global Influenza Surveillance Network under an agreement reached at the Open Ended Working Group that WHO coordinated to support global preparedness for a future influenza pandemic.

April 21, 2011
GSK, Valeant respond to CRL for ezogabine

GlaxoSmithKline and Valeant last week responded to the Food and Drug Administration's complete response letter for the companies' investigational anti-epileptic drug.

April 15, 2011
Despite divestment, expect innovation for brands GSK holds on to

Duh, winning! Because there are no losers in this. GlaxoSmithKline will be able to funnel its extensive marketing dollars into a stable of poised-to-explode brands, niche marketers can take those brands being sold and breathe fresh marketing life into them and retailers now benefit most of all because a greater portfolio of brands are being marketed with gusto.

April 14, 2011
GSK announces divestment of OTC brands

GlaxoSmithKline on Thursday identified the remaining noncore over-the-counter brands that it intends to divest as the company focuses its Consumer Healthcare business around a portfolio of fast-growing priority brands and emerging markets.

April 12, 2011
Former GSK executive named Safeway SVP

Darren Singer, a 25-year GlaxoSmithKline veteran, has been named Safeway's SVP pharmacy, health and wellness, the retailer announced.

April 12, 2011
Study: POS electronic safety check can reduce heart attack risk among diabetes patients

A point-of-sale safety check may reduce the risk of patients unsafely receiving a drug for Type 2 diabetes that may increase their risk of heart attack, according to a new study conducted by pharmacy benefit manager Prime Therapeutics and scheduled for presentation at the 23rd annual meeting of the Academy of Managed Care Pharmacy in Minneapolis.

April 7, 2011
Horizant OKed as restless legs syndrome treatment

The Food and Drug Administration has approved a drug made by GlaxoSmithKline and Xenoport for treating restless legs syndrome, the agency said Thursday.

© 2013 Drug Store News. All Rights Reserved.